Across every clinical trial, Pharma and Biotech companies have a dire need to access patients in efficient numbers and to conduct their study to the highest quality possible. Every sponsor faces the same problems, these being the lack of high performing sites available, with eligible patients to power studies forward, leading to study delays, unforeseen and extra study costs. To meet this industry demand CRU extended its national site network to a Global Site Network in 2017 with a corporate objective of offering CRU’s sponsors what they need – high number of patients in good quality as soon as possible.